Literature DB >> 2663650

Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine.

V A Snewin1, S M England, P F Sims, J E Hyde.   

Abstract

To investigate the genetic basis of drug resistance in human malaria parasites, we have sequenced the entire dihydrofolate reductase thymidylate synthetase DHFR-TS bifunctional gene from the highly pyrimethamine-resistant K1 isolate of Plasmodium falciparum. The protein is predicted to consist of 607 amino acids (aa), (71,685 Da), with an N-terminal methionine encoded by the second start codon of the open reading frame. Compared to the sequence from drug-sensitive parasites, there are two nucleotide changes in the coding region which bring about a substitution of Arg for Cys at aa position 59 and Asn for Thr at aa position 108. Both changes occur in regions of the DHFR domain involved in inhibitor and cofactor binding and are hence strongly implicated in drug resistance. The gene is present as a single copy in both K1 and drug-sensitive FCR3 isolates, and is assigned to chromosome 4. Codon usage follows the pattern observed in that of malarial surface antigen genes, with the exception fo codons corresponding to Val and Pro. The Asn and Lys contents of the predicted protein are exceptionally high, these residues being particularly concentrated in the DHFR and junction domains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663650     DOI: 10.1016/0378-1119(89)90006-1

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  26 in total

1.  A search for sources of drug resistance by the 4D-QSAR analysis of a set of antimalarial dihydrofolate reductase inhibitors.

Authors:  O A Santos-Filho; A J Hopfinger
Journal:  J Comput Aided Mol Des       Date:  2001-01       Impact factor: 3.686

2.  Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania.

Authors:  Richard J Pearce; Chris Drakeley; Daniel Chandramohan; Frank Mosha; Cally Roper
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Comparison of dinucleotide frequency and codon usage in Toxoplasma and Plasmodium: evolutionary implications.

Authors:  A M Johnson
Journal:  J Mol Evol       Date:  1990-04       Impact factor: 2.395

4.  Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand.

Authors:  Mallika Imwong; Sasithon Pukrittayakamee; Qin Cheng; Catrin Moore; Sornchai Looareesuwan; Georges Snounou; Nicholas J White; Nicholas P J Day
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure.

Authors:  Mallika Imwong; Sasithon Pukrittayakamee; Laurent Rénia; Franck Letourneur; Jean-Paul Charlieu; Ubolsree Leartsakulpanich; Sornchai Looareesuwan; Nicholas J White; Georges Snounou
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 6.  Exploring the folate pathway in Plasmodium falciparum.

Authors:  John E Hyde
Journal:  Acta Trop       Date:  2005-04-18       Impact factor: 3.112

7.  Accessible mutational trajectories for the evolution of pyrimethamine resistance in the malaria parasite Plasmodium vivax.

Authors:  Pan-Pan Jiang; Russell B Corbett-Detig; Daniel L Hartl; Elena R Lozovsky
Journal:  J Mol Evol       Date:  2013-09-27       Impact factor: 2.395

8.  Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.

Authors:  Alyson M Auliff; John H Adams; Michael T O'Neil; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

9.  Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates.

Authors:  M Imwong; S Pukrittakayamee; S Looareesuwan; G Pasvol; J Poirreiz; N J White; G Snounou
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Biguanide-atovaquone synergy against Plasmodium falciparum in vitro.

Authors:  K Jones; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.